119 articles from STAT, Phys.org, Medium and more. Refreshed every few hours.
Subtítulo: E se a evolução não for apenas sobre sobrevivência, mas sobre um sistema computacional que encapsula a história em camadas de… Continue reading on Medium »
The threat of cyberattacks against American agriculture and food systems is growing, and Washington State University researchers are helping to lead a call for a national consortium of land-grant universities to study and combat the threat.
The gifts and payments that doctors receive from drugmakers increased inappropriate prescribing, likely leading to rising health care costs, according to a new review.
Life Biosciences said yesterday that three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug, with no serious adverse events.
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
The FDA flagged a potential safety signal after four patient deaths in a trial testing a schizophrenia drug, Argenx faces an unusual setback, and more pharma news.
For decades, scientists have believed that a protein called interferon tau (IFNT) is indispensable for pregnancy in cattle. Produced by the early embryo, it was thought to signal its presence to the mother and prevent the hormonal changes that would otherwise end the pregnancy.
How has the NIH been spending its budget? And why are biotech investors feeling gloomy? Find out on this week's episode of "The Readout LOUD" podcast.
Roche is partnering with Chinese startup Defand Therapeutics to discover new medicines.
Argenx said its blockbuster drug Vyvgart didn’t outperform placebo in a Phase 3 trial of patients with Sjögren's disease, a chronic autoimmune disorder.
Roche has inked a drug discovery deal with Chinese biotech Defand Therapeutics, focused on molecular glue medicines.
“Don’t google,” the pediatric geneticist warned. It took me five years to disobey.
Smaller biotech firms are trying to figure out how to win exemptions from Trump's import taxes.
Crawling through muddy soybean fields to inspect several plant-mounted microphones was not on Emily Sur's graduate school bingo card, but she's not mad about it. Her research offers a unique opportunity to work at the intersection of entomology, agriculture and emerging technologies while still doing what she loves.
The brand drug industry’s main trade group is suing the Trump administration over a pilot program tying Medicare drug prices to those in peer countries.
In a setback for Merck, a Dutch court ordered a halt to the manufacturing and marketing of a subcutaneous formulation of Keytruda in several European countries.
Forbion, a prominent European venture capital firm, said it has raised $2.6 billion, its largest fundraise to date and one of the largest in the region in recent years.
The Justice Department issued a new directive for combating fraud that noted the agency will pursue violations of a federal law that tightly regulates the pharmaceutical industry.
For most people with hemophilia B, treatment means regular infusions of clotting factor IX, often for life. In April 2025, China’s drug… Continue reading on Medium »
Exon-skipping drugs present a critical test for the FDA’s goal of encouraging treatments for rare disease.
Caribou Biosciences is shutting down after failing to raise the money necessary to fund a late-stage clinical trial of its off-the-shelf CAR-T therapy for lymphoma.
Farmers use a manufactured version of a natural plant hormone called gibberellic acid to improve the health and growth of crops, but it is highly sensitive to heat and light. A study in the Journal of the Science of Food and Agriculture shows that loading gibberellic acid into biodegradable nanoparticles can improve grape yield and quality, making it a promising and environmentally friendly approach for sustainable agricultural production.
How Scientists Are Breeding Smart Crops to Survive Extreme Droughts; Continue reading on Medium »
AstraZeneca opened a new R&D site in Kendall Square yesterday, celebrating a $1 billion investment in the unsettled center of U.S. biotechnology after a spate of Chinese dealmaking.
Stem cells might be the next peptides, and how Trump's $90 checks will play out after the election.
“Telling more people they have cancer is not progress; progress is having fewer people die from cancer,” H. Gilbert Welch writes of Grail’s multicancer screening test.
Eli Lilly’s Jaypirca has won FDA approval for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
Vaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.
What science says so far about which cancers can be beat by vaccines — and which will require more creative approaches.
A melanoma vaccine succeeded in a late-stage clinical trial. The question now is whether other cancer vaccines will work — and whether mRNA is up to the task.
Peptides gained legitimacy at the FDA after being embraced by MAHA. Advocates hope stem cell treatments will follow the same path.
Modern biology increasingly depends on experiments that examine biological processes at the molecular level. Researchers study molecular… Continue reading on Medium »
Databases around the world contain information on millions upon millions of enzymes that have the potential to degrade pollutants like plastic. Scientists at Murdoch University's Bioplastics Innovation Hub are combining machine learning technology and biochemistry to identify which of these enzymes have the potential to break down plastic and other harmful pollutants.
Eli Lilly is launching LillyDirect to deliver Mounjaro straight to Australian patients’ doors — and local doctors and pharmacists aren’t thrilled.
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Why have so many Americans lost trust in science? And what's the deal with a new gene-editing lawsuit? Find out on this week's episode of "The Readout LOUD" podcast.
Chinese-designed drugs now account for roughly half the global pipeline. STAT's Jason Mast traveled to Shanghai to get an up-close look at the competition that's making American's nervous.
Health care companies dominate the MAHA Summit, and a look at Trump's watered down effort to lower Medicare drug prices.
DHS has appealed a court ruling blocking it from restricting how long international students and postdoctoral researchers can remain in the U.S.
Questions about the durability of an experimental Huntington's disease therapy matter to Wall Street. They matter less to those directly affected by the disease.
The small biotech company Invivyd is developing an injectable, low-dose monoclonal antibody to protect against Covid.
In Washington, Eric Cantor will confront bipartisan backlash over rising health care costs.
A small conference with big ambitions mirrors the rapid growth of Chinese biotech, invites comparisons to U.S. biotech gathering also known for deal-making.
The human genome contains roughly 3 billion DNA letters, and changing just one of them can sometimes influence how our biology works. The… Continue reading on Medium »
New research from the DTU National Food Institute and Aarhus University shows that microorganisms can be used to specifically alter the amino acid composition of plant-based foods, making them more nutritious and therefore healthier.
Federal health officials want to speed up clinical research to compete with countries like China.
Biodegradable films made from engineered honeybee silk could form the basis of a new generation of "smart" wound dressings, according to researchers at CSIRO and Adelaide University.
An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.
Free for your first hundred saves. No card needed.